Isomorphic Labs President Predicts All Future Drugs Will Be AI-Designed

Isomorphic Labs President Max Jaderberg predicted that all future drugs will eventually be designed by artificial intelligence. Speaking at the Bloomberg Technology Summit, he emphasized that the company is actively working to accelerate this transition through its preclinical drug discovery pipelines. This prediction highlights the ambitious vision of leading AI biotech firms to fundamentally reshape pharmaceutical research, which has traditionally relied on slow and costly trial-and-error methods. Backed by massive funding and high valuations, companies like Isomorphic Labs are steering the industry toward fully computational drug discovery. Isomorphic Labs, a spin-off from Google DeepMind led by Demis Hassabis, develops proprietary AI models targeting diseases such as cancer, immune system disorders, and inflammation. The company has raised approximately $2.7 billion and is reportedly in talks for a new funding round that could value it at $40 billion or higher.